Physician profile
Timothy W Powell
NPI 1982697090
$2,280.23
in general payments reported to CMS, 2019-2025
10 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $123 · 2021: $1,513 · 2022: $14.02 · 2023: $180 · 2024: $127 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.33 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,010.06 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $61.58 | 2022-2024 | Rytary |
| Teva Pharmaceuticals USA, INC. | $50.64 | 2019 | |
| Ucb, INC. | $38.98 | 2023 | Fintepla |
| Neurelis, INC. | $26.32 | 2021-2024 | Valtoco |
| Pfizer INC. | $23.72 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.10 | 2023 | Onivyde, Somatuline Depot |
| Sk Life Science, INC. | $18.94 | 2023 | |
| Greenwich Biosciences, INC. | $18.79 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.